Despite chemotherapy and immunotherapy, the average survival of patients with advanced small-cell lung cancer is just 12 months. The SAKK 15/19 trial will examine whether radiotherapy and the administration of durvalumab could slow down the progression of the disease.

The trial is open to patients who have advanced small-cell lung cancer in which there are metastases or where the tumor volume in the lung is so large that curative radiotherapy is not possible as a first treatment. 

For more information on where and how this trial is conducted, consult the trial website.